Study Brain Derived Neurotrophic Factor Gene Modified Schwann Cells Combined Chitosan Materials Treatment Peripheral Nerve Injury

BDNF (Brain Derived Neurotrophic Factor) gene-modified Schwann cells combined with tissue engineering to treat peripheral nerve injury. Morphology, immunohistochemistry, tissue engineering techniques, and functional assessment were used to determine the effects of transgenic PN injury. Transplantation of modified SCs from ex vivo replanted grafts expressing BDNF, and for the secretion of CNTF or NT3 form. The graft was used to repair a unilateral 1 cm defect of the rat phrenic nerve and the outcome was observed after 10 weeks. In this study, except for CNTF (Immunostained axon minimal) which is similar in all grafts, the number of regenerated beta III-Tubulin-positive axons was also studied. The number of fibers in the cell-free, untransduced SCs and NT3 groups was found to be significantly reduced while using the PanNF antibody, indicating a lack of largecaliber axons. Additionally, it contains the most number of sensory fibers, which is identified by IB 4 or CGRP. Semi-thin section and ultrathin section examination showed uneven graft morphology, especially in BDNF and NT3 grafts, with obvious aggregation tissues. In NT3 grafts, unmyelinated axons are loosely organized in many Remak bundles, and the BDNF group has the lowest proportion of the most refined axons, myelin axons. Gait analysis showed that the standing posture width of CNTF and NT3 transplanted rats was increased, while the injured left hind limb length of NT3 transplanted rats increased significantly, indicating that the sensory sensitivity of these animals was enhanced. In conclusion, expression of different types of neurotrophic factors, such as BDNF, CNTF, or NT3, by transgenic SCs will deliver different effects on PN graft morphology, number, type of regenerated axons, and myelination.